WNK kinases: Molecular regulators of integrated epithelial ion transport

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 5, 2004, Pages 557-562

  Kahle, Kristopher T ^a   Wilson, Frederick H ^a   Lalioti, Maria ^a   Toka, Hakan ^a   Qin, Hui ^a   Lifton, Richard P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epithelia; Hypertension; Kinases; Na Cl cotransporter (NCCT); Paracellular; Renal outer medullary potassium channel (ROMK)

Indexed keywords

COTRANSPORTER; POTASSIUM CHANNEL; POTASSIUM ION; PROTEIN KINASE; PROTEIN KINASE WNK1; PROTEIN KINASE WNK4; PROTEIN SERINE THREONINE KINASE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CELL MEMBRANE PERMEABILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ELECTROLYTE BALANCE; ELECTROLYTE EXCRETION; ENZYME ASSAY; ENZYME LOCALIZATION; ENZYME REGULATION; HOMEOSTASIS; HUMAN; ION CURRENT; ION TRANSPORT; KIDNEY EPITHELIUM; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MUTATION; MUTATIONAL ANALYSIS; NEPHRON; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOHYPOALDOSTERONISM; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EPITHELIUM; HUMANS; ION TRANSPORT; KIDNEY; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; PSEUDOHYPOALDOSTERONISM; SIGNAL TRANSDUCTION;

EID: 4344656182     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200409000-00012     Document Type: Review

References (27)

1. Paver WK, Pauline GJ. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust 1964; 35:305-306.
2. Gordon RD, Klemm SA, Tunny TJ, Stowasser M. Hypertension: pathophysiology, diagnosis, and management. In: Laragh JH, Brenner BM, editors. New York: Raven; 1995. pp. 2111-2123.
3. Schambelan M, Sebastian A, Rector FC Jr. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. Kidney Int 1981; 19:716-727.
4. Take C, Ikeda K, Kurasawa T, Kurokawa K. Increased chloride reabsorption as an inherited renal tubular defect in familial type II pseudohypoaldosteronism. N Engl J Med 1991; 324:472-476.
5. Mansfield TA, Simon DB, Farfel Z, et al. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. Nat Genet 1997; 16:202-205.
6. Disse-Nicodeme S, Achard JM, Desitter I, et al. A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal dominant form of hypertension. Am J Hum Genet 2000; 67:302-310.
7. Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 5532:1107-1112.
8. Kamide K, Takiuchi S, Tanaka C, et al. Three novel missense mutations of WNK4, a kinase mutated in inherited hypertension, in Japanese hypertensives: implication of clinical phenotypes. Am J Hypertens 2004; 17:446-449.
9. Xu B, English JM, Wilsbacher JL, et al. WNK1, a novel mammalian serine/ threonine protein kinase lacking the catalytic lysine in subdomain II. J Biol Chem 2000; 275:16795-16801.
10. Xu BE, Min X, Stippec S, et al. Regulation of WNK1 by an autoinhibitory domain and autophosphorylation. J Biol Chem 2002; 277:48456-48462.
11. Mayan H, Vered I, Mouallem M, et al. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 2002; 87:3248-3254.
12. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996; 12:24-30.
13. Wilson FH, Kahle KT, Sabath E, et al. Molecular pathogenesis of inherited hypertension with hyperkalemia; the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A 2003; 100:680-684. This study demonstrates the inhibition of NCCT by WNK4 and that inhibition is kinase-dependent and results from the loss of NCCT from the cell surface. Both PHAII mutations tested lose inhibitory activity.
14. Yang CL, Angell J, Mitchell R, et al. WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 2003; 111:1039-1045. This study demonstrates the inhibition of NCCT by WNK4, and suggests that WNK1 inhibits WNK4.
15. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104:545-556.
16. + secretion. Nat Genet 2003; 35:372-376. This study established that WNK4 inhibits ROMK activity and that PHAII mutations show increased inhibition. It established that WNK4 can independently regulate NCCT and ROMK, explaining the PHAII phenotype and establishing WNK4 as a molecular switch.
17. Yamauchi K, Rai T, Kobayashi K, et al. Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proc Natl Acad Sci U S A 2004; 101:4690-4694. This study provides evidence for the role of WNK4 in the regulation of paracellular chloride ion flux.
18. Kahle KT, MacGregor GG, Hebert SC, et al. WNK4 regulates paracellular CI permeability [Abstract]. American Society of Nephrology, Philadelphia, USA, 2004; in press.
19. Choate KA, Kahle KT, Wilson FH, et al. WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse CI-transporting epithelia. Proc Natl Acad Sci U S A 2003; 100:663-668.
20. - flux in extrarenal epithelia. Proc Natl Acad Sci U S A 2004; 101:2064-2069. This study demonstrates the presence of WNK4 in polarized epithelia in diverse tissues involved in chloride ion flux.
21. Wang Z, Yang CL, Ellison DH. Comparison of WNK4 and WNK1 kinase and inhibiting activities. Biochem Biophys Res Commun 2004; 317:939-944.
22. O'Reilly M, Marshall E, Speirs HJ, et al. WNK1, a gene within a novel blood pressure control pathway, tissue-specifically generates radically different isoforms with and without a kinase domain. J Am Soc Nephrol 2003; 14:2447-2456. The demonstration of a kidney-specific WNK1 isoform without a kinase domain, and its expression in the DCT of the nephron.
23. Delaloy C, Lu J, Houot AM, et al. Multiple promoters in the WNK1 gene: one controls expression of a kidney-specific kinase-defective isoform. Mol Cell Biol 2003; 23:9208-9221. The demonstration of multiple transcription start sites and WNK1 isoforms in the kidney, as well as a conserved enhancer element conserved among genes expressed in DCT.
24. Zambrowicz BP, Abuin A, Ramirez-Solis R, et al. WNK1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci U S A 2003; 100:14109-14114. The targeted disruption of WNK1 is homozygous lethal; however, the heterozygous knockout mouse shows reduced blood pressure.
25. Vitari AC, Deak M, Collins BJ, et al. WNK1, the kinase mutated in an inherited high-blood-pressure syndrome, is a novel PKB (protein kinase B)/Akt substrate. Biochem J 2004; 378:257-268. This interesting finding raises the possibility that insulin signaling may regulate WNK activity.
26. Xu BE, Stippec S, Lenertz L, et al. WNK1 activates ERK5 by a MEKK2/3-dependent mechanism. J Biol Chem 2004; 279:7826-7831. This study puts WNK1 upstream of ERK5 signaling.
27. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997; 277:1624-1632.